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ABSTRACT 25 
Objectives: To investigate the role of fluid intake from beverages before and after a 26 
diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence. 27 
Study design: Prospective cohort study. Methods: 716 patients with non-muscle invasive 28 
bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour 29 
(TURBT) and completed self-administrated questionnaires on usual fluid intake from 30 
beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over 31 
the year after diagnosis), were included. Multivariable Cox regression was used to calculate 32 
hazard ratios and 95% confidence intervals of developing recurrent bladder cancer in relation 33 
to the intake of total fluid, total alcohol, and individual beverages. Results: During 2,025 34 
person-years of follow-up, 238 (33%) of the included 716 NMIBC patients developed one or 35 
more recurrences of bladder cancer. Total fluid intake before diagnosis was not associated 36 
with a first recurrence of bladder cancer when comparing the highest and lowest intake group 37 
(HR=0.98, 95% C.I. 0.70-1.38, p=0.91). Comparable results were obtained for total fluid 38 
intake pre-diagnosis and the risk of developing multiple recurrences of bladder cancer 39 
(HR=1.01, 95% C.I. 0.87-1.19, p=0.85). A total of 379 of the 716 patients reported on usual 40 
fluid intake within 1 year of diagnosis. No significant associations between total fluid intake 41 
1 year after diagnosis and a first recurrence of bladder cancer were found when comparing 42 
the highest and lowest intake group (HR=0.91; 95% C.I. 0.60-1.37, p=0.65) or with multiple 43 
recurrences of bladder cancer (HR=1.06; 95% C.I. 0.89-1.26, p=0.54). In addition, total 44 
alcohol intake and individual beverages were not associated with bladder cancer recurrence. 45 
Conclusions:  The results indicate that an individual’s fluid intake from beverages is unlikely 46 
to have an important role in bladder cancer recurrence.  47 
  48 
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INTRODUCTION 49 
Non-muscle-invasive bladder cancer (NMIBC) is the most common malignancy of the 50 
urinary tract and has a high rate of recurrence despite adequate therapy. Identification of 51 
modifiable risk factors could reduce the risk of developing recurrences and improve 52 
prognosis. The  urogenous contact theory hypothesizes that an increased voiding frequency 53 
may reduce bladder cancer risk [1,2]. By increasing the intake of fluids, potential carcinogens 54 
present in the urine are diluted and the voiding frequency stimulated. By reducing the contact 55 
time of carcinogens with the bladder urothelium, the risk of bladder cancer decreases. On the 56 
contrary, it has been suggested that when the bladder wall is extended from a high volume of 57 
urine, carcinogens can come into contact with deeper layers of the bladder urothelium and 58 
increase bladder cancer risk [3]. In addition, in some parts of the world drinking water 59 
contaminated with a high concentration of arsenic could increase the risk of bladder cancer 60 
[4]. It is conceivable that the theories about fluid intake and the risk of developing bladder 61 
cancer represent a modifiable factor of importance in bladder cancer prognosis as well [5–7]; 62 
it would be a compelling strategy to simply increase or decrease fluid intake to decrease the 63 
risk of recurrence. To our knowledge, only Donat et al. [8] investigated the impact of total 64 
fluid intake on tumour recurrence in patients with NMIBC. At each visit, all patients 65 
undergoing surveillance for recurring tumours completed a self-administered fluid intake 66 
questionnaire that measured total fluid intake during a 24-hour period. Results of this study 67 
indicated that daily fluid intake levels did not affect recurrence and that the types of fluids 68 
imbibed may be more important than the total amount [8]. Therefore, the present study 69 
investigates the role of individual beverages, total alcohol and total fluid intake (over the year 70 
before and the year after diagnosis) and the risk of developing one or more recurrences of 71 
bladder cancer. 72 
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METHODS 
The Bladder Cancer Prognosis Programme 
This study is part of the Bladder Cancer Prognosis Programme (BCPP), a prospective cohort 
study in the West Midlands region of England. Details of the cohort have been published 
previously [9]. Briefly, during the enrolment period (December 2005 - October 2011), a total 
of 1,550 male and female patients (age ≥18 years) were enrolled based on abnormal 
cystoscopic findings suggestive of bladder cancer. Transurethral resection of the primary 
bladder tumour (TURBT) was followed by cytoscopic surveillance. Optimal additional 
treatment comprised intravesical chemotherapy with mitomycin C within 24 hours of 
TURBT and/or a course of further mitomycin C or intravesical BCG, as per contemporary 
European Association of Urology guidelines. Bladder cancer recurrence was defined as the 
new occurrence of a non-muscle invasive bladder cancer (stage Ta, T1, or pTis) at the same 
or at a different site as the initial primary bladder tumour and excluding recurrence identified 
at the first check cystoscopy. Written informed consent was obtained from all participants. 
The study protocol was approved by the Nottingham Research Ethics Committee 
(06/MRE04/65) and registered on ClinicalTrials.gov (NCT00553566).  
 
Data collection 
Around the time of diagnosis, just prior to, or just post TURBT,, data on medical history, 
socio-demographics, quality of life, and health-related lifestyle (including dietary intake) 
were collected by a trained research nurse using semi-structured face-to-face interviews and a 
questionnaire. The research nurse and patient went through the questionnaire page by page. 
Patients were asked about habitual dietary intake over the previous year. The developed 
version of the food-frequency questionnaire (FFQ) aims to assess the dietary intake, by 
asking the participants to report the frequency of consumption of approximately 16-line items 
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over the last year. More specifically, the frequency of fluid intake from beverages asked in 
the questionnaire consisted of six levels: never or less than once per month, one to three times 
per month, once a week, two to four times per week, five to six times per week, or at least 
once per day. For each drink, a measure size was provided (e.g. cup, (small) glass, pub 
measure (2.5cl), or (half) pint glass). The frequency of intake of each beverage was 
multiplied by their measure size to calculate the millilitres of fluids consumed per day. Total 
fluid intake was computed as the sum of servings of all beverages in the questionnaire: wine-
champagne, fortified wine, beer, cider, spirits, liqueurs, coffee, tea, hot chocolate, soup, 
ovaltine-horlicks, fizzy pop, pure fruit juice, fruit squash, milk, and water. Total alcohol 
intake included alcoholic beverages only: wine-champagne, fortified wine, beer, cider, spirits, 
and liqueurs. Repeated fluid intake from beverages was collected through a postal follow-up 
questionnaire one year after diagnosis.  
 
Exclusion criteria 
A total of 244 participants with no evidence of a bladder tumour (T0), patients who had a 
tumour that could not be assessed (Tx) (n=116), who had muscle invasive bladder cancer 
(MIBC) (n=275), who received no TURBT (n=16), who had radiotherapy (on suspicion of 
MIBC) (n=8), who had incomplete data on tumour characteristics (e.g. stage, grade, size, 
multiplicity) (n=53) and smoking (n=94), and had missing data on pre-diagnosis fluid intake 
(n=28), were all excluded from this study (Figure 1). The final analysis for fluid intake over 
the year before diagnosis comprised 716 patients. More than a third of these 716 patients did 
not complete a follow-up questionnaire one year after diagnosis (n=278) or developed a 
recurrence of bladder cancer before completing the follow-up questionnaire (n=59). 
Therefore, a total of 379 patients remained for investigating the association between fluid 
intake over the year after diagnosis and bladder cancer recurrence.  
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 Statistical Analysis 
According to the UK government recommendations on eating healthy and achieving a 
balanced diet, anybody living in a maritime climate should consume at least 1,200 mL of 
fluids from drinks a day [10]. Patients were divided into three groups: a group with an intake 
of 250mL – 850mL of total fluid per day, a group consuming 850mL – 1,200 mL of total 
fluid per day, or a group with a total intake of more than the recommended 1,200 mL of fluid 
per day. Patients became at risk for a recurrence of bladder cancer from the date of TURBT 
and remained at risk until the earliest occurrence of a recurrence, cystectomy, death, the most 
recent surveillance cystoscopy, or study end (five years post-TURBT). Cox regression was 
used to calculate hazard ratios (HRs) and 95% confidence intervals (95% C.I.) of developing 
a first recurrence of bladder cancer in relation to total fluid intake, total alcohol intake, and 
individual beverages. To identify possibly influential outliers in total fluid and alcohol intake, 
Cook's Distance was used. The association of fluid intake with recurrent bladder cancer was 
examined in both crude and multivariate models. Confounders were considered a priori 
based on known prognostic factors for NMIBC recurrence from the European Association of 
Urology guidelines and included: age at diagnosis (continuous) [11], sex (male/female) [12], 
smoking status (never/former/current smoker) [13], and tumour characteristics including 
stage (pTa/pT1/pTis), grade (1/2/3), size of largest tumour (diameter <3cm/≥3cm), and 
tumour multiplicity (1/>1) [14–16].  
Conditional risk set modelling was applied to investigate time to each recurrent event and 
analysis time was reset at each event [17]. For this analysis, re-resection of tumours (yes/no) 
was added as a confounder. The proportional hazards assumption was checked in all models 
using Schoenfeld residuals [18]. Cumulative incidence functions (CIF) accounting for 
competing risks (death and cystectomy) were made [19]. These models are conditional as the 
failure times are conditional on the occurrence of the prior recurrence, i.e. a second 
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recurrence cannot occur before the first recurrence. P-values were 2-sided with a significance 
level of 0.05. All statistical analyses were performed using Stata software version 14.  
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RESULTS 
Baseline characteristics and number of recurrences 
During 2,025 person-years of follow-up (mean (SD) follow-up 3.7 (1.5) years), 238 (33%) of 
the 716 NMIBC patients developed one or more recurrences of bladder cancer. More 
specifically, 80 (34%) of these 238 patients developed a second recurrence, 35 (15%) a third 
recurrence, 17 (8%) a fourth recurrence, five (3%) a fifth recurrence, two (1%) a sixth 
recurrence, and one (1%) a seventh recurrence. Patient characteristics at diagnosis and initial 
treatment are presented in Table 1. The median age at diagnosis was 71 years and most 
patients were male (80%), Caucasian (97%), and current or former smokers (86%). The 
average intake of fluid was relatively evenly distributed between patients who had a 
recurrence of bladder cancer and those who had not (mean total fluid intake 1,087 mL per 
day and 1,103 mL per day, respectively).  
 
Total fluid intake and bladder cancer recurrence 
Table 2 presents HRs with corresponding 95% C.I. for total fluid intake over the year before 
diagnosis from beverages and time to a first bladder cancer recurrence and multiple bladder 
cancer recurrences among 716 NMIBC patients. Total fluid intake the year before diagnosis 
did not affect the recurrence of a first bladder tumour (HR= 0.98, 95% C.I. 0.70-1.38, 
p=0.91) when adjusted for age, sex, smoking status, stage, grade, and tumour size and 
multiplicity. The association between total fluid intake the year before diagnosis and time to 
multiple recurrences showed similar results (HR= 1.01, 95% C.I. 0.87-1.19, p=0.85) when 
adjusted for the same confounders and tumour re-resection (second transurethral resection).  
Table 3 presents the results for the remaining 379 NMIBC patients on total fluid intake after 
diagnosis – no significant associations were observed between total fluid intake and the 
development of a first bladder cancer recurrence (HR=0.91; 95% C.I. 0.60-1.37, p=0.65) or 
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multiple recurrences (HR=1.06; 95% C.I. 0.89-1.26, p=0.54) when corrected for known 
prognostic factors for NMIBC recurrence provided in the European Association of Urology 
guidelines (including age, sex, smoking status, tumour characteristics and tumour re-
resection).  
 
Total alcohol and individual beverages intake and bladder cancer recurrence 
Results of the Cox proportional hazard models predicting the development of recurrence 
based on total alcohol intake and individual beverages can be found in the online 
supplementary file (Table S1-S8). Among 716 NMIBC patients, total alcohol intake before 
diagnosis (highest intakes >125mL versus lowest intakes 0mL) was not associated with a first 
bladder tumour (HR= 0.97; 95% CI 0.70-1.36) in the most extensive model (adjusted for age, 
sex, smoking status, stage, grade, and tumour size and multiplicity) (Table S1). Similar 
results were found for total alcohol intake prior to a diagnosis of bladder cancer and multiple 
recurrences of bladder cancer (HR= 0.97; 95% CI 0.84-1.11) when corrected for the same 
confounders as in the time to a first recurrence analysis plus re-resection of a bladder tumour 
(Table S2).  
None of the individual alcoholic beverages including beer, cider, wine/champagne, fortified 
wine, spirits or liqueurs consumed prior to bladder cancer diagnosis influenced the risk of 
developing a first or multiple recurrences of bladder cancer when comparing the highest 
frequency of intake ‘at least 1 per day’ versus the lowest frequency of intake /never/less than 
1 per month’ (Table S1-S2). The warm beverages coffee, tea, hot chocolate, ovaltine/horlicks 
and soup were also investigated. No associations were found when comparing the frequencies 
of these warm beverages (at least one per day versus never/less than 1 per month before 
diagnosis) and a first or multiple recurrences of bladder cancer (Table S3-S4). In addition, 
pre-diagnosis consumption of the cold beverages milk, water, fizzy pop, pure fruit juice, and 
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fruit squash/cordial, did not affect the development of one or multiple recurrences of bladder 
cancer when comparing the highest versus the lowest frequency intakes.  
Among the 379 NMIBC that remained for analyses one year after a diagnosis of bladder 
cancer, total alcohol intake was not associated with a first recurrence (HR= 1,01; 95% CI 
0.65-1.58) or multiple recurrences (HR= 1,05; 95% CI 0.88-1.25) (Table S5-S6). 
Consumption of alcoholic beverages one year after a diagnosis of bladder cancer was not 
related to the development of bladder cancer recurrences (Table S5-S6). Finally, no 
associations were found for usual warm and hot non-alcoholic beverages consumption and 
one or more recurrence of bladder cancer (Table S7-S8).  
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DISCUSSION 
The results of this study indicate that there is no evidence of an association between total 
fluid, total alcohol, or individual beverages (before and after diagnosis) and recurrence of a 
bladder tumour in patients diagnosed for NMIBC. These results are consistent with the 
findings of Donat et al. [8] who also concluded it remains unclear whether increased total 
fluid intake is beneficial against the development of bladder cancer recurrence. With regard 
to fluid intake and the risk of developing bladder cancer for the first time, the results of a 
recent case-control study have shown that there was no association with total water intake 
from both beverages and foods [20]. Also the results of a meta-analysis demonstrated no 
association between total fluid intake and the risk of developing primary bladder cancer [21]. 
However, subgroup analyses indicated that high fluid intake could increase the risk of 
bladder cancer in European men (and possibly American men) and decrease the risk of 
bladder cancer in Asian men [21].  
It seems plausible, however, that substances in beverages could be involved in carcinogenesis 
in the bladder as they come into contact with the bladder urothelium when excreted via the 
urine. The numerous substances may react differently with cells of the bladder urothelium 
and be involved in several different pathways associated with cancer pathogenesis including 
inflammation, cell survival and self-renewal of cancer stem cells [22,23]. A possible 
explanation for the lack of an association between fluid intake from beverages and bladder 
cancer recurrence could be that tumour recurrence is more influenced by tumour biology, 
field cancerization, and cancer treatment than continued exposure of potential carcinogens 
with the bladder urothelium [24–26]. Incomplete resection of the primary tumour and tumour 
cell re-implantation remain to be the most influential factors in the development of NMIBC 
recurrence [26]. Finally, it is inevitable that fluid intake was not measured without error - 
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recall bias and measurement errors in dietary intake cannot be excluded and are a common 
limitation of epidemiological studies.  
CONCLUSIONS 
The results of this study indicate that fluid intake from beverages is unlikely to have a 
dominant  role in influencing the risk of subsequent recurrence(s). Proposed strategies aimed 
at decreasing contact time of carcinogens with the urothelium by increasing fluid intake are 
unlikely to delay or prevent the development of bladder cancer recurrence in NMIBC 
patients.  
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Figure 1. Flow diagram of patients selection, with exclusion criteria   
 
 
1,550 patients suggestive of bladder 
cancer 
1,306 patients suggestive of bladder 
cancer 
244 patients had no evidence of a 
bladder tumour  
1,190 patients suggestive bladder 
cancer 
116 patients had a tumour that 
could not be  
assessed (Tx) 
915 patients with non-muscle 
invasive bladder cancer (NMIBC) 
275 patients had muscle invasive 
bladder cancer (MIBC) 
16 patients received no 
transurethral resection of bladder 
tumour (TURBT) 
899 patients with NMIBC 
8 patients received radiotherapy 
after TURBT 
891 patients with NMIBC 
53 patients had incomplete data 
on tumour characteristics 
(including stage, grade, size 
tumour, number of tumours) 838 patients with NMIBC 
94 patients had incomplete data 
on smoking status 
744 patients with NMIBC 
28 patients had incomplete data 
on fluid intake 
716 patients with NMIBC 
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Table legends: 
 
Table 1. Patient characteristics at diagnosis for 716 NMIBC patients treated with 
transurethral resection of a primary bladder tumour 
 
Table 2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional 
hazard models predicting a first and multiple recurrences of bladder cancer, based on total 
fluid consumed in the year before diagnosis, in 716 NMIBC patients 
 
Table 3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional 
hazard models predicting a first and multiple recurrences of bladder cancer, based on total 
fluid consumed in the year after diagnosis, in 379 NMIBC patients 
 
Online Supplemental Tables S1-S8. Hazard ratios (HR) and 95% confidence intervals (95% 
C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of 
bladder cancer, based on alcohol intake from beverages and individual beverages consumed 
in the year before and in the year after diagnosis 
  
 14 
Where the data contains missing values the percentages do not add up to 100%  
Table 1. Patient characteristics at diagnosis for 716 NMIBC patients treated with transurethral resection of a primary 
bladder tumour 
  Number (%) 
Age at time of diagnosis (years) 
median (25th-75th percentile) 71 (63-77)  
Sex Male 573 (80%) 
 Female 143 (20%) 
Smoking status Current smokers 335 (47%) 
 Former smokers 281 (39%) 
 Never smokers 100 (14%) 
Alcohol consumption Drinkers 540 (75%) 
 Non-drinkers 176 (25%) 
Educational level High 89 (12%) 
 Middle 91 (13%) 
 None/Low 163 (23%) 
BCG intravesical immunotherapy Yes 111 (15%) 
 No 275 (39%) 
Mitomycin C intravesical chemotherapy Yes 337 (47%) 
 No 73 (10%) 
Tumour stage pTa 478 (67%) 
 pT1 232 (32%) 
 pTis 6 (1%) 
Tumour grade 1 206 (29%) 
 2 261 (36%) 
 3 249 (35%) 
Size largest tumour (cm) <3 449 (63%) 
 ≥3 267 (37%) 
Tumours multiplicity 1 427 (59%) 
 >1 289 (41%) 
No of recurrences over 5 years 0 478 (67%) 
 1 158 (22%) 
 >1 80 (11%) 
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 Table 2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total 
fluid intake over the year before diagnosis, in 716 NMIBC patients 
 
   
Model 1* 
  
Model 2** 
  
Model 3*** 
   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p for trend 
Time to first recurrence          
250-850 mL 205 64 ref . ref . ref . 0.86 
850 – 1200 mL 257 98 1.24 (0.90-1.69) 0.19 1.26 (0.92-1.72) 0.16 1.17 (0.85-1.62) 0.33  
>1200 mL 254 76 0.92 (0.66-1.28) 0.62 0.93 (0.67-1.31 0.70 0.98 (0.70-1.38) 0.91  
          
Time to multiple recurrences          
250-850 mL 205 92 ref . ref . ref . 0.78 
850 – 1200 mL 257 171 0.95 (0.83-1.09) 0.48 0.96 (0.84-1.10) 0.57 0.95 (0.83-1.08) 0.42  
>1200 mL 254 115 1.05 (0.90-1.22) 0.51 1.05 (0.90-1.23) 0.54 1.01 (0.87-1.19) 0.85  
*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and 
multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second 
transurethral resection) 
  
 Table 3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total fluid intake over 
the year after diagnosis, in 379 remaining NMIBC patients 
 
   
Model 1* 
  
Model 2** 
  
Model 3*** 
   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p for trend 
Time to first recurrence          
250-850 mL 116 45 ref . ref . ref . 0.65 
850 – 1200 mL 124 48 1.08 (0.72-1.63) 0.71 1.04 (0.69-1.57) 0.86 1.07 (0.71-1.61) 0.76  
>1200 mL 139 46 0.81 (0.54-1.21) 0.31 0.80 (0.53-1.20) 0.27 0.91 (0.60-1.37) 0.65  
          
Time to multiple recurrences          
250-850 mL 116 67 ref . ref . ref . 0.53 
850 – 1200 mL 124 71 1.07 (0.91-1.25) 0.41 1.06 (0.91-1.24) 0.43 1.08 (0.91-1.27) 0.38  
>1200 mL 139 68 1.05 (0.87-1.26) 0.63 1.04 (0.86-1.26) 0.67 1.06 (0.89-1.26) 0.54  
*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and 
multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second 
transurethral resection) 
 17 
REFERENCES 
[1] Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992;6:1–30. 
[2] McDONALD DF, LUND RR. The role of the urine in vesical neoplasm. I. Experimental confirmation of the urogenous theory of 
pathogenesis. J Urol 1954;71:560–70. 
[3] Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H. Life-style and occupational risk factors in cancer of the 
lower urinary tract. Am J Epidemiol 1986;124:578–89. 
[4] World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, 
Physical Activity and Bladder Cancer. 2015. n.d. 
[5] Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, et al. Fluid intake and the risk of bladder cancer in men. N 
Engl J Med 1999;340:1390–7. doi:10.1056/NEJM199905063401803. 
[6] Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the health professionals follow-
up study cohort. Am J Epidemiol 2012;175:696–705. doi:10.1093/aje/kwr359. 
[7] Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 
2011;50:167–78. doi:10.3109/0284186X.2010.529822. 
[8] Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J 
 18 
Urol 2003;170:1777–80. doi:10.1097/01.ju.0000091803.35049.da. 
[9] Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, et al. The West Midlands Bladder cancer prognosis 
programme: Rationale and design. BJU Int 2010;105:784–8. doi:10.1111/j.1464-410X.2009.08849.x. 
[10] Public Health England in association with the Welsh government, Food Standards Scotland and the Food Standards Agency in Northern 
Ireland. The Eatwell Guide. n.d. 
[11] Taylor JA, Kuchel GA. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract 
Urol 2009;6:135–44. doi:10.1038/ncpuro1315. 
[12] Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, 
staging, and prognosis. World J Urol 2011;29:457–63. doi:10.1007/s00345-011-0709-9. 
[13] Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for 
recurrent bladder cancer. Cancer 2014;120:408–14. doi:10.1002/cncr.28394. 
[14] Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer: a contemporary 
review of the literature. J Urol 1998;160:645–59. 
[15] Yan Y, Andriole GL, Humphrey PA, Kibel AS. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of 
bladder and effects of clinicopathologic and biochemical factors. Cancer 2002;95:1239–46. doi:10.1002/cncr.10822. 
 19 
[16] Ather MH, Nazim SM. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. Korean J Urol 2015;56:553. 
doi:10.4111/kju.2015.56.8.553. 
[17] Amorim LDAF, Cai J. Modelling recurrent events: A tutorial for analysis in epidemiology. Int J Epidemiol 2015;44:324–33. 
doi:10.1093/ije/dyu222. 
[18] D. Schoenfeld. Partial Residuals for The Proportionnal Hazards Regression Model. Biometrika 1982;69:239–41. 
[19] Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new 
representations of old estimators. Stat Med 1999;18:695–706. 
[20] Di Maso M, Bosetti C, Taborelli M, Montella M, Libra M, Zucchetto A, et al. Dietary water intake and bladder cancer risk: An Italian 
case–control study. Cancer Epidemiol 2016;45:151–6. doi:10.1016/j.canep.2016.09.015. 
[21] Liu Q, Liao B, Tian Y, Chen Y, Luo D, Lin Y, et al. Total fluid consumption and risk of bladder cancer: a meta-analysis with updated 
data. Oncotarget 2017;8:55467–77. doi:10.18632/oncotarget.18100. 
[22] Prasad S, Phromnoi K, Yadav V, Chaturvedi M, Aggarwal B. Targeting Inflammatory Pathways by Flavonoids for Prevention and 
Treatment of Cancer. Planta Med 2010;76:1044–63. doi:10.1055/s-0030-1250111. 
[23] Kim YS, Farrar W, Colburn NH, Milner JA. Cancer stem cells: potential target for bioactive food components. J Nutr Biochem 
2012;23:691–8. doi:10.1016/j.jnutbio.2012.03.002. 
 20 
[24] Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal 
cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835–41. 
[25] Simon R, Eltze E, Schäfer KL, Bürger H, Semjonow A, Hertle L, et al. Cytogenetic analysis of multifocal bladder cancer supports a 
monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 2001;61:355–62. 
[26] Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng K, Wallace DMA, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann 
R Coll Surg Engl 2010;92:519–24. doi:10.1308/003588410X12664192076935. 
 
 
 
 
  
 21 
SUPPLEMENTARY DATA ‘Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder 
cancer: a prospective cohort study’ 
Pre-diagnosis analysis 
Table S1. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on total alcohol and 
beverage-specific alcohol intake 1 year before diagnosis (n=716) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p trend 
Total alcohol*         0.93 
T1 (0 mL/day) 176 60 ref . ref . ref .  
T2 (25 mL-125 mL/day) 231 75 0.91 (0.65-1.28) 0.60 0.94 (0.67-1.32) 0.72 0.90 (0.63-1.27) 0.55  
T3 (>125 mL/day) 306 102 0.95 (0.69-1.30) 0.74 1.00 (0.72-1.40) 0.98 0.97 (0.70-1.36) 0.87  
Beer (e.g. beer, lager, stout)          
Never/less than 1 per month 316 108 ref . ref . ref . 0.56 
1-3 per month 92 26 0.77 (0.50-1.18) 0.23 0.83 (0.53-1.28) 0.40 0.81 (0.52-1.27) 0.36  
1 per week 68 31 1.38 (0.91-2.08) 0.13 1.46 (0.95-2.24) 0.08 1.41 (0.92-2.15) 0.11  
2-4 per week 141 42 0.82 (0.58-1.17) 0.27 0.87 (0.61-1.25) 0.46 0.88 (0.61-1.27) 0.50  
5-6 per week 44 14 0.89 (0.52-1.51) 0.66 0.95 (0.55-1.63) 0.84 0.78 (0.45-1.35) 0.37  
At least 1 per day 55 16 0.85 (0.50-1.45) 0.55 0.90 (0.52-1.55) 0.69 0.93 (0.54-1.58) 0.78  
Cider          
Never/less than 1 per month 667 215 ref . ref . ref . 0.26 
1-3 per month 28 14 2.11 (1.26-3.54) 0.00 2.29 (1.40-3.76) 0.00 1.96 (1.15-3.37) 0.01  
1 per week 11 5 1.36 (0.58-3.17) 0.48 1.31 (0.58-2.98) 0.51 1.17 (0.57-2.38) 0.67  
2-4 per week 5 2 1.66 (0.32-8.62) 0.54 2.07 (0.40-10.81) 0.39 2.38 (0.49-11.51) 0.28  
5-6 per week 1 0 - . - . - .  
At least 1 per day 4 1 0.65 (0.09-4.65) 0.67 0.68 (0.10-4.81) 0.70 0.90 (0.16-5.25) 0.91  
Wine or champagne          
Never/less than 1 per month 412 133 ref . ref . ref . 0.32 
1-3 per month 74 21 0.84 (0.54-1.32) 0.45 0.87 (0.56-1.37) 0.55 0.84 (0.53-1.34) 0.47  
1 per week 55 20 1.19 (0.71-1.98) 0.52 1.25 (0.74-2.11) 0.41 1.38 (0.82-2.30) 0.22  
2-4 per week 89 29 0.92 (0.62-1.38) 0.69 0.95 (0.63-1.41) 0.78 0.98 (0.65-1.46) 0.91  
5-6 per week 36 14 1.25 (0.71-2.21) 0.43 1.25 (0.72-2.17) 0.43 1.21 (0.69-2.11) 0.50  
At least 1 per day 50 20 1.19 (0.75-1.88) 0.46 1.18 (0.75-1.86) 0.47 1.25 (0.78-2.01) 0.36  
*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose 
consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day. 
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S1. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p trend 
Fortified wine (e.g. port, sherry, cinzano)          
Never/less than 1 per month 625 208 ref . ref . ref . 0.54 
1-3 per month 49 13 0.70 (0.41-1.22) 0.21 0.70 (0.41-1.19) 0.19 0.70 (0.41-1.18) 0.18  
1 per week 20 6 0.80 (0.37-1.76) 0.59 0.73 (0.33-1.60) 0.43 0.81 (0.38-1.74) 0.59  
2-4 per week 12 5 1.27 (0.55-2.94) 0.58 1.31 (0.59-2.92) 0.50 1.52 (0.66-3.50) 0.32  
5-6 per week 6 3 1.85 (0.60-5.74) 0.29 1.70 (0.60-4.81) 0.32 1.40 (0.51-3.84) 0.51  
At least 1 per day 4 2 1.99 (0.34-11.59) 0.44 2.09 (0.36-12.19) 0.41 2.49 (0.45-13.72) 0.29  
Spirits (e.g. gin, brandy, rum, vodka, whiskey)          
Never/less than 1 per month 455 140 ref . ref . ref . 0.88 
1-3 per month 91 38 1.34 (0.93-1.93) 0.12 1.42 (0.98-2.05) 0.06 1.42 (0.98-2.06) 0.06  
1 per week 53 23 1.50 (0.98-2.30) 0.06 1.50 (0.99-2.29) 0.06 1.58 (1.03-2.43) 0.04  
2-4 per week 66 21 1.00 (0.64-1.58) 1.00 1.03 (0.65-1.62) 0.91 1.08 (0.68-1.72) 0.74  
5-6 per week 15 5 1.11 (0.46-2.69) 0.81 1.06 (0.44-2.55) 0.90 1.01 (0.40-2.60) 0.98  
At least 1 per day 36 10 0.86 (0.46-1.63) 0.65 0.83 (0.44-1.56) 0.57 0.80 (0.43-1.48) 0.47  
Liqueurs (e.g. tia maria, baileys, cointreau)          
Never/less than 1 per month 671 220 ref . ref . ref . 0.05 
1-3 per month 31 9 0.83 (0.43-1.63) 0.59 0.83 (0.43-1.62) 0.59 0.77 (0.39-1.52) 0.45  
1 per week 6 2 0.93 (0.22-3.91) 0.92 0.89 (0.21-3.68) 0.87 0.85 (0.21-3.43) 0.81  
2-4 per week 5 3 2.45 (0.67-9.02) 0.18 2.16 (0.58-8.09) 0.25 1.73 (0.46-6.46) 0.42  
5-6 per week 0 0 - . - . - .  
At least 1 per day 3 3 4.76 (2.63-8.62) 0.00 4.72 (2.75-8.11) 0.00 6.66 (4.56-9.74) 0.00  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.  
 23 
Table S2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on total alcohol 
and beverage-specific alcohol intake 1 year before diagnosis (n=716) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p trend 
Total alcohol*          
T1 (0 mL/day) 176 145 ref . ref . ref . 0.87 
T2 (25 mL-125 mL/day) 231 204 0.89 (0.77-1.02) 0.10 0.89 (0.77-1.03) 0.11 0.88 (0.77-1.02) 0.08  
T3 (>125 mL/day) 306 265 0.98 (0.87-1.11) 0.75 0.99 (0.86-1.13) 0.83 0.97 (0.84-1.11) 0.66  
Beer (e.g. beer, lager, stout)          
Never/less than 1 per month 316 166 ref . ref . ref . 0.52 
1-3 per month 92 38 0.97 (0.79-1.19) 0.76 0.98 (0.79-1.21) 0.83 0.96 (0.78-1.19) 0.73  
1 per week 68 63 1.03 (0.88-1.22) 0.69 1.04 (0.87-1.25) 0.65 1.05 (0.88-1.24) 0.61  
2-4 per week 141 58 1.08 (0.94-1.24) 0.28 1.09 (0.93-1.28) 0.27 1.08 (0.93-1.26) 0.31  
5-6 per week 44 27 0.97 (0.79-1.20) 0.80 0.99 (0.78-1.24) 0.90 0.88 (0.69-1.14) 0.33  
At least 1 per day 55 32 1.12 (0.92-1.35) 0.26 1.11 (0.90-1.37) 0.32 1.09 (0.88-1.37) 0.42  
Cider          
Never/less than 1 per month 667 348 ref . ref . ref . 0.25 
1-3 per month 28 22 1.04 (0.85-1.26) 0.70 1.03 (0.85-1.25) 0.76 1.00 (0.82-1.23) 0.98  
1 per week 11 10 0.88 (0.63-1.22) 0.44 0.87 (0.65-1.17) 0.37 0.87 (0.68-1.12) 0.29  
2-4 per week 5 3 3.27 (1.61-6.63) 0.00 3.34 (1.72-6.48) 0.00 3.64 (1.90-6.97) 0.00  
5-6 per week 1 0 - . - . - .  
At least 1 per day 4 1 2.45 (2.02-2.98) 0.00 2.56 (2.11-3.12) 0.00 2.76 (2.19-3.46) 0.00  
Wine or champagne          
Never/less than 1 per month 412 210 ref . ref . ref . 0.91 
1-3 per month 74 33 1.15 (0.91-1.45) 0.25 1.15 (0.91-1.46) 0.24 1.18 (0.94-1.48) 0.17  
1 per week 55 26 1.35 (1.03-1.76) 0.03 1.35 (1.04-1.75) 0.03 1.29 (0.97-1.71) 0.08  
2-4 per week 89 49 1.03 (0.88-1.22) 0.69 1.03 (0.87-1.21) 0.75 1.01 (0.86-1.18) 0.90  
5-6 per week 36 33 0.84 (0.67-1.06) 0.14 0.86 (0.69-1.08) 0.19 0.89 (0.71-1.12) 0.33  
At least 1 per day 50 33 1.03 (0.87-1.23) 0.74 1.02 (0.86-1.21) 0.83 1.03 (0.86-1.22) 0.78  
*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose 
consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day. 
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S2. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% C.I.) p-value HR (95% C.I.) p-value HR (95% C.I.) p-value p trend 
Fortified wine (e.g. port, sherry, cinzano)          
Never/less than 1 per month 625 334 ref . ref . ref . 0.48 
1-3 per month 49 20 1.05 (0.81-1.37) 0.71 1.06 (0.82-1.37) 0.67 1.06 (0.83-1.35) 0.64  
1 per week 20 11 0.85 (0.56-1.30) 0.45 0.87 (0.57-1.34) 0.53 0.88 (0.58-1.35) 0.56  
2-4 per week 12 11 0.85 (0.65-1.12) 0.25 0.83 (0.65-1.06) 0.13 0.83 (0.70-0.99) 0.04  
5-6 per week 6 6 0.92 (0.78-1.08) 0.30 0.91 (0.77-1.08) 0.29 0.93 (0.73-1.18) 0.55  
At least 1 per day 4 2 1.54 (0.93-2.54) 0.09 1.54 (0.98-2.44) 0.06 1.52 (0.90-2.58) 0.12  
Spirits (e.g. gin, brandy, rum, vodka, whiskey)          
Never/less than 1 per month 455 218 ref . ref . ref . 0.45 
1-3 per month 91 73 0.94 (0.81-1.09) 0.40 0.93 (0.79-1.08) 0.34 0.91 (0.78-1.06) 0.23  
1 per week 53 42 0.97 (0.82-1.15) 0.75 0.97 (0.82-1.15) 0.70 1.00 (0.84-1.18) 0.96  
2-4 per week 66 28 1.00 (0.80-1.25) 0.99 1.01 (0.80-1.26) 0.96 0.98 (0.76-1.25) 0.84  
5-6 per week 15 8 1.17 (0.88-1.55) 0.29 1.19 (0.89-1.59) 0.25 1.25 (0.99-1.58) 0.06  
At least 1 per day 36 15 1.18 (0.87-1.60) 0.28 1.17 (0.87-1.58) 0.31 1.18 (0.87-1.59) 0.29  
Liqueurs (e.g. tia maria, baileys, cointreau)          
Never/less than 1 per month 671 355 ref . ref . ref . 0.67 
1-3 per month 31 13 1.08 (0.78-1.49) 0.65 1.07 (0.77-1.50) 0.68 0.96 (0.64-1.42) 0.82  
1 per week 6 7 0.89 (0.61-1.29) 0.53 0.88 (0.59-1.30) 0.51 0.82 (0.56-1.22) 0.34  
2-4 per week 5 5 1.18 (0.75-1.85) 0.47 1.21 (0.74-1.99) 0.44 1.22 (0.74-2.00) 0.44  
5-6 per week 0 0 - . - . - .  
At least 1 per day 3 4 0.82 (0.60-1.11) 0.19 0.80 (0.57-1.12) 0.19 0.89 (0.64-1.23) 0.47  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection).  
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Table S3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on non-alcoholic 
beverage intake 1 year before diagnosis (n=716) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% C.I.) p-value HR (95% CI) p-value HR (95% C.I.) p-value p trend 
Coffee          
Never/less than 1 per month 152 39 ref . ref . ref . 0.16 
1-3 per month 39 15 1.60 (0.88-2.91) 0.12 1.79 (0.99-3.22) 0.05 1.84 (1.00-3.38) 0.05  
1 per week 46 14 1.13 (0.63-2.04) 0.68 1.19 (0.65-2.17) 0.58 1.03 (0.54-1.96) 0.94  
2-4 per week 78 27 1.35 (0.83-2.22) 0.23 1.36 (0.83-2.24) 0.22 1.34 (0.81-2.21) 0.26  
5-6 per week 34 13 1.43 (0.75-2.70) 0.27 1.58 (0.83-3.00) 0.16 1.46 (0.77-2.75) 0.25  
At least 1 per day 367 129 1.32 (0.92-1.88) 0.13 1.36 (0.94-1.96) 0.10 1.37 (0.94-2.00) 0.10  
Tea          
Never/less than 1 per month 73 21 ref . ref . ref . 0.54 
1-3 per month 11 4 1.60 (0.54-4.72) 0.39 1.58 (0.53-4.66) 0.41 1.34 (0.43-4.14) 0.61  
1 per week 1 0 - . - . - .  
2-4 per week 13 7 2.17 (0.99-4.77) 0.05 2.13 (0.96-4.74) 0.06 2.10 (0.92-4.76) 0.08  
5-6 per week 24 11 1.83 (0.91-3.70) 0.09 1.81 (0.89-3.67) 0.10 1.58 (0.78-3.20) 0.20  
At least 1 per day 594 194 1.23 (0.81-1.87) 0.32 1.18 (0.77-1.79) 0.45 1.21 (0.80-1.83) 0.37  
Hot chocolate          
Never/less than 1 per month 548 179 ref . ref . ref . 0.73 
1-3 per month 70 24 1.16 (0.76-1.77) 0.50 1.19 (0.78-1.81) 0.42 1.05 (0.68-1.61) 0.84  
1 per week 26 7 0.74 (0.36-1.52) 0.42 0.75 (0.37-1.54) 0.44 0.74 (0.35-1.58) 0.44  
2-4 per week 29 13 1.43 (0.83-2.46) 0.20 1.39 (0.82-2.38) 0.23 1.16 (0.68-2.00) 0.58  
5-6 per week 4 0 - . - . - .  
At least 1 per day 39 14 1.22 (0.68-2.17) 0.50 1.15 (0.64-2.07) 0.64 1.26 (0.70-2.25) 0.44  
Ovaltine / Horlicks          
Never/less than 1 per month 634 212 ref . ref . ref . 0.51 
1-3 per month 21 5 0.61 (0.26-1.39) 0.24 0.61 (0.27-1.39) 0.24 0.61 (0.26-1.47) 0.27  
1 per week 12 4 1.10 (0.38-3.22) 0.86 1.09 (0.38-3.11) 0.87 1.02 (0.35-2.95) 0.97  
2-4 per week 16 7 1.38 (0.66-2.87) 0.39 1.27 (0.61-2.64) 0.52 1.19 (0.57-2.48) 0.65  
5-6 per week 6 2 1.06 (0.28-4.02) 0.93 1.10 (0.29-4.22) 0.89 1.29 (0.33-5.02) 0.71  
At least 1 per day 27 7 0.66 (0.31-1.41) 0.28 0.64 (0.30-1.37) 0.25 0.70 (0.32-1.50) 0.36  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S3. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Soup          
Never/less than 1 per month 219 70 ref . ref . ref . 0.13 
1-3 per month 167 66 1.27 (0.91-1.78) 0.16 1.27 (0.91-1.78) 0.16 1.27 (0.91-1.78) 0.17  
1 per week 141 47 1.07 (0.74-1.55) 0.70 1.02 (0.71-1.48) 0.91 1.02 (0.70-1.48) 0.91  
2-4 per week 148 47 1.07 (0.74-1.55) 0.71 1.03 (0.71-1.50) 0.88 1.03 (0.71-1.51) 0.86  
5-6 per week 18 3 0.49 (0.15-1.56) 0.23 0.46 (0.14-1.47) 0.19 0.44 (0.13-1.49) 0.19  
At least 1 per day 23 4 0.47 (0.17-1.32) 0.15 0.44 (0.16-1.22) 0.11 0.44 (0.17-1.15) 0.09  
Fizzy pop (e.g. lemonade, cola)          
Never/less than 1 per month 437 154 ref . ref . ref . 0.49 
1-3 per month 71 23 1.00 (0.64-1.57) 1.00 1.05 (0.67-1.65) 0.83 1.06 (0.67-1.67) 0.82  
1 per week 55 14 0.66 (0.39-1.13) 0.13 0.70 (0.41-1.20) 0.19 0.69 (0.41-1.17) 0.17  
2-4 per week 68 19 0.79 (0.49-1.28) 0.34 0.82 (0.51-1.33) 0.43 0.81 (0.50-1.31) 0.40  
5-6 per week 14 2 0.33 (0.08-1.35) 0.12 0.33 (0.08-1.32) 0.12 0.34 (0.08-1.47) 0.15  
At least 1 per day 71 25 1.03 (0.68-1.57) 0.88 1.05 (0.69-1.61) 0.81 1.08 (0.70-1.65) 0.73  
Pure fruit juice (e.g. orange, apple)          
Never/less than 1 per month 275 86 ref . ref . ref . 0.38 
1-3 per month 82 33 1.38 (0.94-2.03) 0.10 1.43 (0.97-2.11) 0.07 1.54 (1.05-2.26) 0.03  
1 per week 72 21 1.02 (0.62-1.66) 0.94 1.11 (0.67-1.81) 0.69 1.09 (0.67-1.78) 0.72  
2-4 per week 103 27 0.80 (0.52-1.24) 0.32 0.87 (0.56-1.35) 0.52 0.90 (0.57-1.40) 0.63  
5-6 per week 42 20 1.68 (1.01-2.80) 0.05 1.71 (1.03-2.84) 0.04 1.76 (1.04-2.98) 0.03  
At least 1 per day 142 50 1.14 (0.81-1.61) 0.45 1.15 (0.81-1.62) 0.43 1.18 (0.83-1.67) 0.35  
Fruit squash or cordial          
Never/less than 1 per month 390 129 ref . ref . ref . 0.81 
1-3 per month 60 19 0.92 (0.57-1.48) 0.72 0.91 (0.57-1.48) 0.71 1.04 (0.64-1.71) 0.87  
1 per week 64 17 0.80 (0.48-1.32) 0.39 0.82 (0.49-1.36) 0.43 0.83 (0.51-1.36) 0.46  
2-4 per week 72 25 1.04 (0.68-1.59) 0.86 1.06 (0.69-1.63) 0.78 1.03 (0.67-1.59) 0.90  
5-6 per week 29 10 1.01 (0.54-1.90) 0.97 1.03 (0.54-1.96) 0.93 1.10 (0.58-2.10) 0.77  
At least 1 per day 101 37 1.14 (0.79-1.64) 0.49 1.12 (0.77-1.61) 0.56 1.05 (0.73-1.51) 0.79  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S3. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Milk          
Never/less than 1 per month 432 148 ref . ref . ref . 0.37 
1-3 per month 51 16 0.79 (0.49-1.29) 0.35 0.82 (0.50-1.35) 0.44 0.77 (0.47-1.27) 0.31  
1 per week 31 11 1.03 (0.56-1.92) 0.92 1.05 (0.56-1.96) 0.88 0.97 (0.53-1.78) 0.92  
2-4 per week 50 19 1.09 (0.68-1.74) 0.73 1.18 (0.73-1.90) 0.50 1.29 (0.80-2.08) 0.29  
5-6 per week 27 7 0.64 (0.30-1.39) 0.26 0.68 (0.32-1.44) 0.31 0.68 (0.32-1.45) 0.31  
At least 1 per day 125 36 0.79 (0.55-1.14) 0.21 0.80 (0.56-1.16) 0.24 0.83 (0.57-1.20) 0.31  
Water (tap, filtered, or bottled)          
Never/less than 1 per month 86 35 ref . ref . ref . 0.18 
1-3 per month 25 8 0.83 (0.40-1.75) 0.63 0.86 (0.41-1.82) 0.69 0.83 (0.39-1.74) 0.62  
1 per week 33 11 0.80 (0.41-1.58) 0.53 0.82 (0.42-1.62) 0.56 0.77 (0.39-1.52) 0.45  
2-4 per week 47 17 0.92 (0.52-1.64) 0.78 0.97 (0.54-1.73) 0.91 0.83 (0.46-1.49) 0.53  
5-6 per week 51 14 0.73 (0.38-1.40) 0.34 0.79 (0.41-1.53) 0.49 0.80 (0.42-1.56) 0.52  
At least 1 per day 474 152 0.76 (0.53-1.09) 0.14 0.78 (0.54-1.14) 0.20 0.76 (0.52-1.10) 0.14  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity. 
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Table S4. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on non-
alcoholic beverage intake 1 year before diagnosis (n=716) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Coffee          
Never/less than 1 per month 152 50 ref . ref . ref . 0.52 
1-3 per month 39 25 1.00 (0.83-1.21) 0.96 1.01 (0.84-1.21) 0.91 0.99 (0.83-1.19) 0.93  
1 per week 46 26 1.11 (0.81-1.52) 0.52 1.09 (0.79-1.50) 0.59 1.08 (0.78-1.50) 0.63  
2-4 per week 78 53 1.03 (0.87-1.23) 0.69 1.05 (0.88-1.25) 0.59 1.06 (0.88-1.26) 0.55  
5-6 per week 34 21 0.99 (0.74-1.31) 0.92 1.01 (0.76-1.34) 0.93 1.00 (0.76-1.33) 0.99  
At least 1 per day 367 209 0.99 (0.86-1.14) 0.89 0.99 (0.86-1.14) 0.93 0.98 (0.84-1.13) 0.73  
Tea          
Never/less than 1 per month 73 34 ref . ref . ref . 0.82 
1-3 per month 11 7 1.65 (0.75-3.62) 0.21 1.73 (0.83-3.60) 0.14 1.61 (0.81-3.23) 0.18  
1 per week 1 0 - . - . - .  
2-4 per week 13 15 1.14 (0.79-1.64) 0.50 1.16 (0.79-1.69) 0.44 1.11 (0.78-1.59) 0.56  
5-6 per week 24 17 1.05 (0.76-1.46) 0.76 1.08 (0.78-1.51) 0.63 1.02 (0.74-1.42) 0.89  
At least 1 per day 594 311 1.14 (0.90-1.45) 0.28 1.14 (0.90-1.45) 0.29 1.09 (0.86-1.38) 0.47  
Hot chocolate          
Never/less than 1 per month 548 284 ref . ref . ref . 0.74 
1-3 per month 70 39 0.89 (0.77-1.04) 0.15 0.88 (0.75-1.03) 0.10 0.87 (0.74-1.02) 0.09  
1 per week 26 15 0.87 (0.70-1.07) 0.18 0.87 (0.70-1.08) 0.20 0.89 (0.73-1.10) 0.29  
2-4 per week 29 25 1.01 (0.80-1.29) 0.91 1.01 (0.78-1.29) 0.96 0.98 (0.76-1.27) 0.86  
5-6 per week 4 0 - . - . - .  
At least 1 per day 39 21 1.07 (0.87-1.31) 0.52 1.06 (0.87-1.30) 0.58 1.01 (0.82-1.24) 0.94  
Ovaltine / horlicks          
Never/less than 1 per month 634 343 ref . ref . ref . 0.25 
1-3 per month 21 5 0.78 (0.66-0.92) 0.00 0.78 (0.67-0.91) 0.00 0.77 (0.67-0.89) 0.00  
1 per week 12 6 1.64 (0.82-3.25) 0.16 1.68 (0.83-3.38) 0.15 1.79 (0.87-3.67) 0.11  
2-4 per week 16 13 0.97 (0.78-1.22) 0.81 0.98 (0.78-1.24) 0.88 1.02 (0.82-1.26) 0.88  
5-6 per week 6 5 1.65 (1.32-2.06) 0.00 1.64 (1.32-2.03) 0.00 1.74 (1.41-2.15) 0.00  
At least 1 per day 27 12 1.10 (0.89-1.36) 0.39 1.03 (0.81-1.31) 0.80 0.98 (0.75-1.29) 0.89  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S4. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Soup          
Never/less than 1 per month 219 113 ref . ref . ref . 0.37 
1-3 per month 167 108 0.99 (0.86-1.15) 0.93 1.00 (0.86-1.16) 0.99 1.00 (0.86-1.16) 0.97  
1 per week 141 78 0.97 (0.85-1.12) 0.72 0.98 (0.85-1.14) 0.81 0.97 (0.84-1.12) 0.69  
2-4 per week 148 69 1.10 (0.93-1.29) 0.27 1.09 (0.92-1.29) 0.30 1.08 (0.92-1.27) 0.34  
5-6 per week 18 10 0.79 (0.64-0.97) 0.03 0.79 (0.64-0.99) 0.04 0.85 (0.67-1.07) 0.16  
At least 1 per day 23 6 1.70 (0.94-3.09) 0.08 1.68 (0.94-3.00) 0.08 1.63 (0.97-2.74) 0.07  
Fizzy pop (e.g. lemonade, cola)          
Never/less than 1 per month 437 246 ref . ref . ref . 0.33 
1-3 per month 71 38 0.94 (0.78-1.15) 0.57 0.96 (0.79-1.17) 0.68 0.96 (0.80-1.16) 0.68  
1 per week 55 24 1.03 (0.86-1.22) 0.76 1.04 (0.87-1.24) 0.70 1.02 (0.85-1.22) 0.83  
2-4 per week 68 34 1.01 (0.85-1.19) 0.93 1.03 (0.87-1.22) 0.73 1.05 (0.88-1.26) 0.58  
5-6 per week 14 2 0.78 (0.68-0.90) 0.00 0.84 (0.71-0.99) 0.04 0.79 (0.64-0.98) 0.03  
At least 1 per day 71 40 1.11 (0.92-1.33) 0.29 1.11 (0.93-1.33) 0.25 1.09 (0.91-1.31) 0.33  
Pure fruit juice (e.g. orange, apple)          
Never/less than 1 per month 275 142 ref . ref . ref . 0.43 
1-3 per month 82 53 0.93 (0.79-1.09) 0.39 0.92 (0.78-1.08) 0.32 0.95 (0.81-1.11) 0.51  
1 per week 72 36 1.02 (0.83-1.24) 0.88 1.01 (0.83-1.24) 0.89 1.00 (0.82-1.22) 0.98  
2-4 per week 103 35 1.09 (0.90-1.33) 0.37 1.12 (0.92-1.36) 0.27 1.12 (0.91-1.37) 0.29  
5-6 per week 42 39 0.91 (0.75-1.11) 0.36 0.90 (0.73-1.11) 0.32 0.94 (0.76-1.15) 0.55  
At least 1 per day 142 79 0.91 (0.78-1.06) 0.21 0.90 (0.78-1.05) 0.18 0.92 (0.80-1.06) 0.27  
Fruit squash or cordial          
Never/less than 1 per month 390 213 ref . ref . ref . 0.39 
1-3 per month 60 29 0.93 (0.76-1.14) 0.49 0.91 (0.75-1.11) 0.35 0.92 (0.77-1.11) 0.40  
1 per week 64 18 1.19 (0.92-1.52) 0.18 1.16 (0.90-1.50) 0.24 1.13 (0.87-1.47) 0.36  
2-4 per week 72 40 1.01 (0.86-1.19) 0.87 1.00 (0.85-1.19) 0.97 0.97 (0.82-1.16) 0.75  
5-6 per week 29 21 1.02 (0.78-1.33) 0.90 1.04 (0.78-1.38) 0.79 1.04 (0.79-1.37) 0.79  
At least 1 per day 101 63 1.10 (0.93-1.29) 0.27 1.08 (0.92-1.27) 0.34 1.08 (0.92-1.26) 0.35  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S4. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Milk          
Never/less than 1 per month 432 241 ref . ref . ref . 0.25 
1-3 per month 51 20 0.92 (0.79-1.07) 0.30 0.94 (0.81-1.09) 0.42 0.97 (0.83-1.12) 0.66  
1 per week 31 21 1.13 (0.88-1.45) 0.33 1.13 (0.87-1.47) 0.37 1.14 (0.86-1.50) 0.36  
2-4 per week 50 36 0.80 (0.71-0.91) 0.00 0.80 (0.70-0.92) 0.00 0.79 (0.68-0.92) 0.00  
5-6 per week 27 20 0.87 (0.66-1.14) 0.30 0.89 (0.66-1.19) 0.43 0.92 (0.68-1.24) 0.58  
At least 1 per day 125 46 1.01 (0.87-1.17) 0.90 1.00 (0.86-1.16) 1.00 0.98 (0.85-1.14) 0.83  
Water (tap, filtered, or bottled)          
Never/less than 1 per month 86 49 ref . ref . ref . 0.33 
1-3 per month 25 14 0.80 (0.67-0.96) 0.02 0.83 (0.68-1.00) 0.05 0.86 (0.71-1.03) 0.10  
1 per week 33 21 0.69 (0.53-0.89) 0.00 0.68 (0.52-0.89) 0.01 0.71 (0.55-0.91) 0.01  
2-4 per week 47 35 0.97 (0.79-1.19) 0.75 0.97 (0.79-1.20) 0.81 0.98 (0.79-1.22) 0.89  
5-6 per week 51 35 0.91 (0.72-1.14) 0.40 0.93 (0.73-1.17) 0.54 0.94 (0.74-1.19) 0.61  
At least 1 per day 474 230 0.99 (0.83-1.17) 0.89 1.00 (0.84-1.18) 0.96 1.01 (0.85-1.20) 0.91  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection).  
 31 
Post-diagnosis analysis 
 
Table S5. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on total alcohol and 
beverage-specific alcohol intake 1 year after diagnosis (n=379) 
 
   Model 1*  Model 2**  Model 3***   
 n Events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Total alcohol*          
T1 (0 mL/day) 87 32 ref . ref . ref . 0.94 
T2 (25 mL-125 mL/day) 130 49 0.96 (0.62-1.50) 0.85 0.97 (0.62-1.51) 0.88 0.97 (0.62-1.51) 0.89  
T3 (>125 mL/day) 162 58 0.93 (0.61-1.44) 0.76 0.94 (0.60-1.47) 0.79 1.01 (0.65-1.58) 0.96  
Beer (e.g. beer, lager, stout)          
Never/less than 1 per month 169 65 ref . ref . ref . 0.93 
1-3 per month 39 14 0.86 (0.49-1.50) 0.58 0.82 (0.46-1.45) 0.49 0.94 (0.53-1.65) 0.82  
1 per week 43 15 0.86 (0.49-1.52) 0.60 0.90 (0.50-1.60) 0.71 1.00 (0.55-1.81) 0.99  
2-4 per week 60 21 0.87 (0.53-1.41) 0.57 0.84 (0.51-1.38) 0.48 1.00 (0.60-1.69) 0.99  
5-6 per week 24 6 0.58 (0.25-1.33) 0.20 0.56 (0.24-1.35) 0.20 0.65 (0.26-1.65) 0.37  
At least 1 per day 44 18 1.08 (0.64-1.82) 0.78 1.03 (0.59-1.79) 0.92 1.05 (0.60-1.84) 0.86  
Cider          
Never/less than 1 per month 356 129 ref . ref . ref . 0.21 
1-3 per month 15 7 1.45 (0.66-3.19) 0.35 1.60 (0.75-3.40) 0.23 1.43 (0.68-3.04) 0.35  
1 per week 3 0 - . - . - .  
2-4 per week 3 2 2.54 (0.55-11.79) 0.23 2.86 (0.68-11.99) 0.15 4.57 (2.11-9.87) 0.00  
5-6 per week 1 1 4.28 (3.41-5.37) 0.00 3.91 (2.99-5.10) 0.00 5.70 (2.71-12.00) 0.00  
At least 1 per day 1 0 - . - . - .  
Wine or champagne          
Never/less than 1 per month 202 75 ref . ref . ref . 0.36 
1-3 per month 27 8 0.78 (0.38-1.63) 0.51 0.87 (0.41-1.84) 0.72 0.80 (0.38-1.65) 0.54  
1 per week 37 15 1.14 (0.65-2.00) 0.66 1.19 (0.68-2.11) 0.54 1.11 (0.63-1.93) 0.72  
2-4 per week 61 18 0.76 (0.45-1.28) 0.30 0.81 (0.47-1.39) 0.45 0.89 (0.52-1.55) 0.69  
5-6 per week 12 6 1.38 (0.61-3.09) 0.44 1.46 (0.68-3.15) 0.33 1.89 (0.83-4.30) 0.13  
At least 1 per day 40 17 1.21 (0.71-2.07) 0.48 1.26 (0.74-2.13) 0.40 1.29 (0.74-2.24) 0.37  
*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose 
consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day. 
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S5. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Fortified wine (e.g. port, sherry, cinzano)          
Never/less than 1 per month 339 124 ref . ref . ref . 0.55 
1-3 per month 23 11 1.38 (0.73-2.60) 0.33 1.42 (0.76-2.68) 0.28 1.53 (0.84-2.80) 0.16  
1 per week 10 2 0.49 (0.13-1.87) 0.30 0.53 (0.14-1.98) 0.35 0.52 (0.15-1.79) 0.30  
2-4 per week 5 2 0.86 (0.27-2.75) 0.80 0.91 (0.33-2.50) 0.85 0.83 (0.29-2.34) 0.72  
5-6 per week 1 0 - . - . - .  
At least 1 per day 1 0 - . - . - .  
Spirits (e.g. gin, brandy, rum, vodka, whiskey)          
Never/less than 1 per month 243 90 ref . ref . ref . 0.39 
1-3 per month 45 16 0.96 (0.55-1.68) 0.88 0.94 (0.54-1.64) 0.84 1.01 (0.58-1.76) 0.98  
1 per week 19 10 1.46 (0.78-2.71) 0.23 1.44 (0.77-2.72) 0.25 1.39 (0.75-2.58) 0.30  
2-4 per week 42 14 0.88 (0.50-1.53) 0.64 0.86 (0.49-1.49) 0.59 0.81 (0.46-1.44) 0.48  
5-6 per week 9 4 1.12 (0.47-2.66) 0.80 1.07 (0.43-2.67) 0.89 1.30 (0.49-3.41) 0.60  
At least 1 per day 21 5 0.59 (0.25-1.41) 0.24 0.56 (0.24-1.33) 0.19 0.59 (0.26-1.35) 0.21  
Liqueurs (e.g. tia maria, baileys, cointreau)          
Never/less than 1 per month 359 130 ref . ref . ref . 0.82 
1-3 per month 12 5 1.07 (0.48-2.39) 0.88 0.98 (0.45-2.17) 0.97 0.92 (0.40-2.14) 0.85  
1 per week 2 2 15.71 (5.23-47.15) 0.00 18.43 (5.62-60.43) 0.00 15.62 (4.21-58.01) 0.00  
2-4 per week 4 1 0.69 (0.09-5.36) 0.73 0.70 (0.09-5.24) 0.73 0.70 (0.12-4.18) 0.69  
5-6 per week 0 0 -  -  -   
At least 1 per day 2 1 1.42 (0.20-10.29) 0.73 1.21 (0.16-8.86) 0.85 0.94 (0.08-11.14) 0.96  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S6. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on total alcohol 
and beverage-specific alcohol intake 1 year after diagnosis (n=379) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Total alcohol*          
T1 (0 mL/day) 87 79 ref . ref . ref . 0.42 
T2 (25 mL-125 mL/day) 130 124 0.91 (0.77-1.09) 0.31 0.90 (0.76-1.08) 0.26 0.93 (0.78-1.10) 0.38  
T3 (>125 mL/day) 162 142 1.06 (0.89-1.27) 0.50 1.03 (0.86-1.23) 0.75 1.05 (0.88-1.25) 0.60  
Beer (e.g. beer, lager, stout)          
Never/less than 1 per month 169 97 ref . ref . ref . 0.09 
1-3 per month 39 15 0.93 (0.79-1.10) 0.39 0.92 (0.75-1.13) 0.44 0.92 (0.74-1.15) 0.46  
1 per week 43 29 1.23 (0.97-1.56) 0.08 1.27 (0.99-1.64) 0.06 1.31 (1.03-1.65) 0.03  
2-4 per week 60 30 1.11 (0.92-1.34) 0.29 1.10 (0.89-1.36) 0.39 1.06 (0.88-1.29) 0.54  
5-6 per week 24 6 1.17 (0.79-1.73) 0.45 1.16 (0.77-1.74) 0.48 1.16 (0.74-1.82) 0.52  
At least 1 per day 44 36 1.18 (0.99-1.41) 0.07 1.16 (0.96-1.40) 0.13 1.16 (0.95-1.41) 0.16  
Cider          
Never/less than 1 per month 356 197 ref . ref . ref . 0.94 
1-3 per month 15 11 1.13 (0.88-1.44) 0.34 1.06 (0.80-1.40) 0.68 1.00 (0.75-1.33) 0.99  
1 per week 3 0 -  -  -   
2-4 per week 3 4 0.75 (0.51-1.09) 0.13 0.74 (0.50-1.08) 0.11 0.83 (0.56-1.23) 0.36  
5-6 per week 1 1 2.45 (1.93-3.10) 0.00 2.36 (1.85-3.01) 0.00 2.47 (1.53-3.96) 0.00  
At least 1 per day 1 0 - . - . - .  
Wine or champagne          
Never/less than 1 per month 202 113 ref . ref . ref . 0.35 
1-3 per month 27 21 0.87 (0.69-1.10) 0.24 0.86 (0.69-1.08) 0.19 0.88 (0.71-1.09) 0.24  
1 per week 37 22 1.07 (0.91-1.27) 0.39 1.06 (0.90-1.25) 0.51 1.09 (0.90-1.31) 0.38  
2-4 per week 61 25 1.02 (0.82-1.28) 0.84 1.03 (0.82-1.29) 0.79 1.11 (0.89-1.39) 0.35  
5-6 per week 12 9 0.80 (0.54-1.18) 0.26 0.77 (0.53-1.12) 0.17 0.80 (0.55-1.18) 0.26  
At least 1 per day 40 23 1.16 (0.90-1.49) 0.25 1.17 (0.91-1.51) 0.22 1.16 (0.90-1.50) 0.26  
*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose 
consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day. 
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S6. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Fortified wine (e.g. port, sherry, cinzano)          
Never/less than 1 per month 339 194 ref . ref . ref . 0.35 
1-3 per month 23 13 1.04 (0.80-1.35) 0.76 1.07 (0.83-1.39) 0.60 1.08 (0.84-1.38) 0.55  
1 per week 10 4 0.60 (0.36-1.01) 0.05 0.60 (0.36-1.03) 0.06 0.62 (0.36-1.07) 0.09  
2-4 per week 5 2 0.86 (0.64-1.14) 0.30 0.92 (0.63-1.35) 0.68 0.90 (0.63-1.30) 0.58  
5-6 per week 1 0 - . - . - .  
At least 1 per day 1 0 - . - . - .  
Spirits (e.g. gin, brandy, rum, vodka, whiskey)          
Never/less than 1 per month 243 142 ref . ref . ref . 0.55 
1-3 per month 45 34 0.94 (0.77-1.15) 0.54 0.93 (0.77-1.13) 0.49 0.92 (0.77-1.11) 0.41  
1 per week 19 11 0.99 (0.84-1.16) 0.87 1.02 (0.87-1.20) 0.82 0.95 (0.75-1.20) 0.66  
2-4 per week 42 15 1.07 (0.87-1.31) 0.53 1.10 (0.89-1.36) 0.39 1.08 (0.86-1.35) 0.52  
5-6 per week 9 6 1.14 (0.82-1.61) 0.43 1.10 (0.79-1.54) 0.57 1.13 (0.81-1.59) 0.48  
At least 1 per day 21 5 0.99 (0.67-1.46) 0.95 1.01 (0.67-1.53) 0.96 1.08 (0.70-1.68) 0.73  
Liqueurs (e.g. tia maria, baileys, cointreau)          
Never/less than 1 per month 359 202 ref . ref . ref . 0.85 
1-3 per month 12 5 0.88 (0.64-1.21) 0.44 0.92 (0.66-1.29) 0.64 0.90 (0.65-1.24) 0.52  
1 per week 2 3 1.06 (0.58-1.94) 0.84 1.11 (0.62-1.97) 0.73 0.93 (0.51-1.71) 0.82  
2-4 per week 4 2 1.03 (0.77-1.37) 0.84 1.06 (0.79-1.43) 0.70 1.10 (0.79-1.52) 0.57  
5-6 per week 0 0 -  -  -   
At least 1 per day 2 1 0.83 (0.75-0.92) 0.00 0.91 (0.76-1.08) 0.27 0.97 (0.79-1.17) 0.73  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S7. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on non-alcoholic 
beverage intake 1 year after diagnosis (n=379) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Coffee          
Never/less than 1 per month 80 23 ref . ref . ref . 0.13 
1-3 per month 20 7 1.30 (0.54-3.13) 0.55 1.33 (0.56-3.19) 0.52 1.02 (0.41-2.51) 0.97  
1 per week 24 9 1.40 (0.65-3.02) 0.39 1.51 (0.70-3.29) 0.29 1.39 (0.62-3.16) 0.43  
2-4 per week 31 13 1.57 (0.78-3.16) 0.21 1.59 (0.79-3.20) 0.19 1.55 (0.75-3.20) 0.24  
5-6 per week 6 2 1.21 (0.30-4.81) 0.79 1.29 (0.35-4.74) 0.71 0.87 (0.26-2.95) 0.83  
At least 1 per day 218 85 1.37 (0.86-2.19) 0.18 1.42 (0.89-2.27) 0.14 1.44 (0.89-2.31) 0.14  
Tea          
Never/less than 1 per month 37 15 ref . ref . ref . 0.74 
1-3 per month 1 0 - . - . - .  
1 per week 7 3 1.29 (0.35-4.81) 0.70 1.43 (0.40-5.10) 0.58 1.87 (0.60-5.89) 0.28  
2-4 per week 13 7 1.42 (0.64-3.13) 0.39 1.74 (0.80-3.80) 0.16 2.03 (0.91-4.53) 0.08  
5-6 per week 8 3 1.01 (0.35-2.90) 0.99 1.10 (0.41-2.96) 0.85 1.11 (0.41-3.03) 0.84  
At least 1 per day 313 111 1.00 (0.61-1.64) 0.99 1.03 (0.63-1.69) 0.89 1.18 (0.71-1.97) 0.53  
Hot chocolate          
Never/less than 1 per month 311 115 ref . ref . ref . 0.15 
1-3 per month 22 10 1.32 (0.70-2.49) 0.40 1.36 (0.74-2.50) 0.32 1.11 (0.63-1.95) 0.72  
1 per week 17 5 0.74 (0.31-1.74) 0.49 0.76 (0.33-1.75) 0.51 0.55 (0.24-1.26) 0.16  
2-4 per week 15 6 1.07 (0.49-2.36) 0.86 1.06 (0.48-2.36) 0.88 0.86 (0.37-2.01) 0.73  
5-6 per week 0 0 -  -  -   
At least 1 per day 14 3 0.53 (0.17-1.63) 0.27 0.50 (0.16-1.59) 0.24 0.50 (0.15-1.62) 0.24  
Ovaltine / Horlicks          
Never/less than 1 per month 332 119 ref . ref . ref . 0.67 
1-3 per month 11 6 1.82 (0.80-4.15) 0.16 1.89 (0.84-4.22) 0.12 1.71 (0.78-3.76) 0.18  
1 per week 3 0 - . - . - .  
2-4 per week 12 6 1.68 (0.75-3.75) 0.21 1.55 (0.69-3.46) 0.29 1.09 (0.48-2.51) 0.83  
5-6 per week 2 1 1.99 (0.20-20.10) 0.56 1.78 (0.18-18.07) 0.62 1.57 (0.15-16.70) 0.71  
At least 1 per day 19 7 1.05 (0.49-2.25) 0.89 1.11 (0.51-2.39) 0.80 1.13 (0.52-2.45) 0.76  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.  
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Table S7. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Soup          
Never/less than 1 per month 103 33 ref . ref . ref . 0.59 
1-3 per month 101 44 1.50 (0.96-2.34) 0.08 1.54 (0.98-2.42) 0.06 1.53 (0.97-2.39) 0.07  
1 per week 80 30 1.27 (0.77-2.09) 0.35 1.29 (0.78-2.12) 0.32 1.36 (0.81-2.27) 0.24  
2-4 per week 77 26 1.17 (0.69-1.97) 0.57 1.17 (0.68-1.99) 0.57 1.20 (0.70-2.08) 0.51  
5-6 per week 9 3 1.24 (0.35-4.44) 0.74 1.31 (0.38-4.52) 0.67 1.72 (0.53-5.60) 0.37  
At least 1 per day 9 3 1.05 (0.34-3.26) 0.94 1.11 (0.38-3.21) 0.85 1.01 (0.38-2.66) 0.98  
Fizzy pop (e.g. lemonade, cola)          
Never/less than 1 per month 251 95 ref . ref . ref . 0.49 
1-3 per month 23 6 0.62 (0.28-1.37) 0.24 0.62 (0.27-1.39) 0.25 0.53 (0.21-1.30) 0.17  
1 per week 23 9 1.05 (0.53-2.10) 0.88 1.02 (0.51-2.05) 0.96 0.80 (0.41-1.53) 0.50  
2-4 per week 38 14 0.97 (0.54-1.75) 0.92 0.97 (0.54-1.73) 0.92 0.96 (0.53-1.75) 0.90  
5-6 per week 10 3 0.77 (0.27-2.21) 0.62 0.73 (0.26-2.09) 0.56 0.82 (0.26-2.53) 0.72  
At least 1 per day 34 12 0.88 (0.50-1.54) 0.65 0.84 (0.48-1.50) 0.56 0.81 (0.45-1.47) 0.50  
Pure fruit juice (e.g. orange, apple)          
Never/less than 1 per month 144 44 ref . ref . ref . 0.92 
1-3 per month 33 21 2.28 (1.41-3.70) 0.00 2.25 (1.39-3.66) 0.00 2.21 (1.39-3.53) 0.00  
1 per week 38 18 1.73 (0.98-3.07) 0.06 1.76 (0.98-3.16) 0.06 1.88 (1.06-3.35) 0.03  
2-4 per week 55 19 1.09 (0.64-1.84) 0.76 1.07 (0.64-1.80) 0.78 1.10 (0.65-1.86) 0.71  
5-6 per week 3 1 1.02 (0.13-8.29) 0.98 1.13 (0.15-8.47) 0.91 0.91 (0.18-4.48) 0.91  
At least 1 per day 106 36 1.07 (0.69-1.68) 0.76 1.07 (0.68-1.68) 0.77 1.17 (0.73-1.86) 0.51  
Fruit squash or cordial          
Never/less than 1 per month 202 73 ref . ref . ref . 0.35 
1-3 per month 20 4 0.49 (0.18-1.33) 0.16 0.47 (0.17-1.30) 0.15 0.52 (0.20-1.36) 0.18  
1 per week 32 12 1.05 (0.56-1.97) 0.88 1.07 (0.58-2.00) 0.82 0.99 (0.55-1.81) 0.99  
2-4 per week 37 12 0.83 (0.45-1.51) 0.54 0.78 (0.43-1.43) 0.43 0.79 (0.44-1.43) 0.43  
5-6 per week 6 2 0.96 (0.23-4.04) 0.95 0.87 (0.20-3.73) 0.85 0.93 (0.21-4.21) 0.93  
At least 1 per day 82 36 1.19 (0.81-1.76) 0.38 1.21 (0.81-1.80) 0.36 1.26 (0.85-1.88) 0.25  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S7. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Milk          
Never/less than 1 per month 273 107 ref . ref . ref . 0.39 
1-3 per month 12 3 0.58 (0.20-1.72) 0.33 0.57 (0.19-1.71) 0.32 0.47 (0.17-1.31) 0.15  
1 per week 8 2 0.67 (0.15-3.01) 0.60 0.80 (0.17-3.72) 0.78 0.84 (0.17-4.21) 0.83  
2-4 per week 28 7 0.58 (0.27-1.22) 0.15 0.58 (0.28-1.22) 0.15 0.65 (0.31-1.38) 0.26  
5-6 per week 5 3 1.63 (0.70-3.80) 0.26 1.64 (0.73-3.68) 0.23 1.41 (0.56-3.57) 0.47  
At least 1 per day 53 17 0.80 (0.47-1.35) 0.40 0.81 (0.47-1.39) 0.44 0.81 (0.46-1.42) 0.45  
Water (tap, filtered, or bottled)          
Never/less than 1 per month 50 22 ref . ref . ref . 0.27 
1-3 per month 5 2 0.74 (0.18-3.06) 0.68 0.72 (0.16-3.23) 0.66 0.84 (0.21-3.34) 0.81  
1 per week 9 4 1.14 (0.36-3.62) 0.82 1.16 (0.36-3.72) 0.80 1.19 (0.47-3.06) 0.71  
2-4 per week 25 10 0.76 (0.37-1.58) 0.47 0.79 (0.38-1.65) 0.53 1.00 (0.47-2.14) 1.00  
5-6 per week 11 4 0.68 (0.26-1.78) 0.43 0.69 (0.27-1.77) 0.44 0.63 (0.26-1.48) 0.29  
At least 1 per day 279 97 0.70 (0.45-1.11) 0.13 0.75 (0.47-1.22) 0.25 0.79 (0.49-1.28) 0.34  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity. 
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Table S8. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on non-
alcoholic beverage intake 1 year after diagnosis (n=379) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Coffee          
Never/less than 1 per month 80 33 ref . ref . ref . 0.97 
1-3 per month 20 14 0.96 (0.77-1.20) 0.72 0.94 (0.76-1.17) 0.57 0.96 (0.79-1.17) 0.70  
1 per week 24 13 1.15 (0.80-1.64) 0.44 1.10 (0.75-1.61) 0.64 1.02 (0.69-1.51) 0.92  
2-4 per week 31 23 0.98 (0.77-1.25) 0.87 0.99 (0.78-1.26) 0.95 1.03 (0.81-1.31) 0.83  
5-6 per week 6 4 0.88 (0.53-1.47) 0.63 0.92 (0.56-1.53) 0.75 0.79 (0.45-1.37) 0.40  
At least 1 per day 218 126 1.00 (0.85-1.19) 0.98 1.00 (0.85-1.18) 0.98 0.99 (0.83-1.17) 0.90  
Tea          
Never/less than 1 per month 37 22 ref . ref . ref . 0.92 
1-3 per month 1 0 - . - . - .  
1 per week 7 7 1.47 (0.81-2.67) 0.20 1.47 (0.78-2.75) 0.23 1.31 (0.65-2.65) 0.45  
2-4 per week 13 8 1.28 (0.88-1.85) 0.20 1.24 (0.85-1.80) 0.26 1.11 (0.79-1.56) 0.55  
5-6 per week 8 7 0.86 (0.55-1.32) 0.49 0.89 (0.59-1.35) 0.59 0.81 (0.52-1.25) 0.34  
At least 1 per day 313 169 1.18 (0.89-1.56) 0.25 1.17 (0.88-1.56) 0.29 1.06 (0.80-1.42) 0.68  
Hot chocolate          
Never/less than 1 per month 311 170 ref . ref . ref . 0.20 
1-3 per month 22 20 0.92 (0.71-1.19) 0.53 0.93 (0.72-1.18) 0.53 0.86 (0.65-1.13) 0.27  
1 per week 17 10 0.79 (0.63-1.00) 0.05 0.83 (0.66-1.04) 0.10 0.79 (0.62-1.02) 0.07  
2-4 per week 15 9 0.96 (0.72-1.28) 0.78 0.97 (0.73-1.29) 0.83 0.95 (0.73-1.25) 0.73  
5-6 per week 0 0 -  -  -   
At least 1 per day 14 4 0.94 (0.70-1.26) 0.68 1.00 (0.73-1.35) 0.98 0.88 (0.59-1.31) 0.53  
Ovaltine / Horlicks          
Never/less than 1 per month 332 177 ref . ref . ref . 0.20 
1-3 per month 11 7 1.28 (0.87-1.88) 0.21 1.28 (0.84-1.95) 0.25 1.23 (0.82-1.86) 0.32  
1 per week 3 0 - . - . - .  
2-4 per week 12 16 1.04 (0.75-1.45) 0.79 1.11 (0.79-1.55) 0.55 1.09 (0.78-1.53) 0.60  
5-6 per week 2 2 1.09 (0.93-1.28) 0.27 1.12 (0.95-1.32) 0.17 0.92 (0.74-1.15) 0.47  
At least 1 per day 19 11 1.17 (0.85-1.61) 0.33 1.23 (0.89-1.72) 0.21 1.23 (0.89-1.69) 0.21  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S8. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Soup          
Never/less than 1 per month 103 49 ref . ref . ref . 0.28 
1-3 per month 101 63 0.91 (0.77-1.06) 0.23 0.91 (0.78-1.07) 0.27 0.87 (0.74-1.02) 0.09  
1 per week 80 37 0.95 (0.79-1.13) 0.56 0.98 (0.82-1.16) 0.78 0.94 (0.79-1.13) 0.50  
2-4 per week 77 57 1.02 (0.81-1.29) 0.85 1.08 (0.86-1.35) 0.51 1.07 (0.88-1.31) 0.49  
5-6 per week 9 4 0.97 (0.72-1.31) 0.84 1.06 (0.75-1.50) 0.72 1.09 (0.76-1.58) 0.64  
At least 1 per day 9 3 1.03 (0.74-1.43) 0.87 1.18 (0.84-1.66) 0.35 1.01 (0.69-1.48) 0.96  
Fizzy pop (e.g. lemonade, cola)          
Never/less than 1 per month 251 146 ref . ref . ref . 0.06 
1-3 per month 23 11 1.16 (0.80-1.67) 0.44 1.15 (0.82-1.61) 0.42 1.09 (0.77-1.55) 0.63  
1 per week 23 13 1.04 (0.81-1.33) 0.77 1.00 (0.77-1.29) 0.99 0.99 (0.76-1.29) 0.95  
2-4 per week 38 23 0.94 (0.78-1.12) 0.47 0.88 (0.73-1.06) 0.19 0.89 (0.75-1.07) 0.23  
5-6 per week 10 3 0.99 (0.72-1.36) 0.96 0.98 (0.75-1.28) 0.89 0.98 (0.77-1.26) 0.90  
At least 1 per day 34 17 0.83 (0.69-0.99) 0.04 0.84 (0.70-1.01) 0.06 0.84 (0.70-1.01) 0.07  
Pure fruit juice (e.g. orange, apple)          
Never/less than 1 per month 144 69 ref . ref . ref . 0.62 
1-3 per month 33 34 0.97 (0.81-1.16) 0.76 0.98 (0.83-1.17) 0.86 0.99 (0.83-1.19) 0.95  
1 per week 38 25 1.20 (1.00-1.44) 0.05 1.19 (0.98-1.44) 0.08 1.17 (0.97-1.42) 0.10  
2-4 per week 55 31 0.94 (0.78-1.13) 0.50 0.95 (0.80-1.14) 0.61 1.01 (0.83-1.23) 0.92  
5-6 per week 3 1 1.52 (1.25-1.85) 0.00 1.56 (1.27-1.92) 0.00 1.59 (1.14-2.22) 0.01  
At least 1 per day 106 53 1.01 (0.84-1.22) 0.90 1.01 (0.84-1.22) 0.92 1.05 (0.86-1.27) 0.65  
Fruit squash or cordial          
Never/less than 1 per month 202 114 ref . ref . ref . 1.00 
1-3 per month 20 6 1.18 (0.79-1.75) 0.42 1.18 (0.79-1.76) 0.42 1.14 (0.79-1.64) 0.48  
1 per week 32 25 1.19 (0.95-1.49) 0.13 1.18 (0.94-1.46) 0.15 1.15 (0.93-1.43) 0.21  
2-4 per week 37 17 0.96 (0.75-1.23) 0.75 0.96 (0.74-1.24) 0.74 0.90 (0.69-1.18) 0.46  
5-6 per week 6 3 0.72 (0.57-0.91) 0.01 0.76 (0.59-0.99) 0.04 0.77 (0.62-0.95) 0.02  
At least 1 per day 82 48 1.01 (0.85-1.20) 0.90 1.02 (0.85-1.21) 0.85 1.03 (0.87-1.23) 0.72  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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Table S8. (continued) 
 
   Model 1*  Model 2**  Model 3***   
 n events HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value p trend 
Milk          
Never/less than 1 per month 273 160 ref . ref . ref . 0.35 
1-3 per month 12 4 1.10 (0.79-1.53) 0.57 1.05 (0.73-1.50) 0.80 1.09 (0.85-1.41) 0.50  
1 per week 8 2 2.08 (1.39-3.12) 0.00 2.01 (1.37-2.96) 0.00 1.92 (1.39-2.65) 0.00  
2-4 per week 28 10 0.95 (0.72-1.26) 0.74 0.94 (0.72-1.24) 0.66 0.89 (0.66-1.20) 0.46  
5-6 per week 5 4 0.74 (0.60-0.92) 0.01 0.76 (0.63-0.92) 0.00 0.76 (0.57-1.02) 0.06  
At least 1 per day 53 33 1.15 (0.94-1.42) 0.18 1.16 (0.95-1.42) 0.14 1.19 (0.96-1.46) 0.11  
Water (tap, filtered, or bottled)          
Never/less than 1 per month 50 32 ref . ref . ref . 0.57 
1-3 per month 5 2 0.79 (0.64-0.98) 0.03 0.74 (0.54-1.00) 0.05 0.90 (0.68-1.19) 0.47  
1 per week 9 10 0.98 (0.71-1.36) 0.91 0.94 (0.67-1.31) 0.70 1.01 (0.69-1.47) 0.96  
2-4 per week 25 12 0.89 (0.68-1.16) 0.38 0.89 (0.68-1.17) 0.41 0.90 (0.68-1.19) 0.48  
5-6 per week 11 6 0.80 (0.60-1.08) 0.15 0.80 (0.59-1.08) 0.14 0.72 (0.51-1.02) 0.07  
At least 1 per day 279 151 0.99 (0.83-1.18) 0.87 0.97 (0.81-1.16) 0.76 1.04 (0.86-1.26) 0.66  
*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and 
re-resection of a bladder tumour (second transurethral resection). 
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